Dark

Check out our API

ADXN
Addex Therapeutics Ltd
stock NASDAQ ADR

At Close

Jul 24, 2025

8.28USD0.000%(0.00)293

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 21, 2025 9:00:30 AM EDT

8.20USD-0.906%(-0.08)168

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 11, 2022

01:00AM EST Addex to Present at the Swiss Equities Baader Virtual Conference GlobeNewswire Inc

Jan 6, 2022

01:00AM EST Geneva, Switzerland,January 6 2022-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference. GlobeNewswire Inc

Dec 17, 2021

01:00AM EST Addex Raises $10.0 Million in Equity Financing GlobeNewswire Inc

Dec 15, 2021

01:00AM EST Addex Provides Year End Pipeline Development Update GlobeNewswire Inc

Nov 18, 2021

01:00AM EST Addex to Present at the Virtual German Equity Forum GlobeNewswire Inc

Nov 15, 2021

01:00AM EST Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients GlobeNewswire Inc

01:00AM EST Geneva, Switzerland, November 15, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference. GlobeNewswire Inc

Nov 4, 2021

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

02:00AM EDT Addex Reports Q3 2021 Financial Results and Provides Corporate Update GlobeNewswire Inc

Nov 1, 2021

02:00AM EDT Addex Therapeutics to Release Q3 2021 Financial Results and Host GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 6, 2021

01:00AM EDT Geneva, Switzerland, October6, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors Day hosted by VoxiaCommunication (October 7, 2021). The event will take place at the Beau Rivage Hotel in Geneva. GlobeNewswire Inc

Oct 4, 2021

01:00AM EDT Addex to Present at the 10th International Meeting on Metabotropic GlobeNewswire Inc

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

01:07AM EDT Addex Therapeutics Begins Phase 2a Clinical Study With Dipraglurant As A Potential Treatment For Blepharospasm RTTNews

01:00AM EDT Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness GlobeNewswire Inc

01:00AM EDT Geneva, Switzerland, September 29, 2021- Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conference (September 27 - 30, 2021). GlobeNewswire Inc

Sep 22, 2021

07:17AM EDT Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder Benzinga

01:50AM EDT CMTA And Addex Therapeutics Enter Collaboration To Advance GABA B PAM As Potential Treatment For CMT1A RTTNews

01:00AM EDT CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B GlobeNewswire Inc

Sep 8, 2021

01:00AM EDT Geneva, Switzerland, September8, 2021- Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 - 15, 2021). GlobeNewswire Inc

Sep 2, 2021

01:00AM EDT Addex to Present at the Swiss Biotech Day GlobeNewswire Inc

Aug 5, 2021

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

01:00AM EDT -- Strong cash and cash equivalents position atJune 30, 2021 ofCHF18.1M($19.6M) -- Pivotal dipraglurant PD-LID study initiated -- Janssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149 -- Dipraglurant blepharospasm study on track to start in Q3 2021 -- Completed $11.5M fundraising in January 2021 GlobeNewswire Inc

Aug 2, 2021

04:05AM EDT Earnings Scheduled For August 2, 2021 Benzinga

01:00AM EDT Addex Therapeutics to Release Half-Year 2021 Financial Results and GlobeNewswire Inc

01:00AM EDT Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev GlobeNewswire Inc

Jul 29, 2021

01:00AM EDT IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for2022 GlobeNewswire Inc

Jul 7, 2021

01:00AM EDT Addex Therapeutics to Present at Access to Giving Virtual GlobeNewswire Inc

Jul 1, 2021

01:00AM EDT Addex, Stanford University and University of Copenhagen Publish GlobeNewswire Inc

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

01:31AM EDT Addex Therapeutics Enters Sales Agreement With Cantor Fitzgerald To Offer ADSs Through At-the-market Offering Program RTTNews

01:00AM EDT Addex Establishes At-The-Market ADS Equity Sale Program GlobeNewswire Inc

Jun 29, 2021

08:59AM EDT Addex Therapeutics Starts Mid-Stage Study For Dipraglurant In Parkinson's Associated Dyskinesia Benzinga

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

01:04AM EDT Addex Therapeutics Begins Pivotal Phase 2b/3 Study Of Dipraglurant For Dyskinesia Associated With Parkinson's Disease RTTNews

01:00AM EDT Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with GlobeNewswire Inc

Jun 17, 2021

01:17AM EDT Addex Therapeutics Says Shareholders Approved All Proposals Of Board In Its 2021 AGM RTTNews

01:00AM EDT Addex Shareholders Approve All Resolutions at Annual General Meeting GlobeNewswire Inc

Jun 7, 2021

01:04AM EDT Addex Enrolls First Patients In Phase 2 Clinical Study Of JNJ-40411813 In Patients With Epilepsy RTTNews

01:00AM EDT Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy GlobeNewswire Inc

May 24, 2021

01:00AM EDT Geneva, Switzerland, May 24, 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will participate at the virtual Benchmark Company Healthcare House Call Conference on May 26th, 2021 (09:00 16:30 EDT) GlobeNewswire Inc

May 17, 2021

01:00AM EDT Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder GlobeNewswire Inc

May 14, 2021

01:00AM EDT Geneva, Switzerland, May14, 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday 16 June 2021 at 11:00am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva. GlobeNewswire Inc

May 5, 2021

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

01:00AM EDT -- Strong cash and cash equivalents position at March31, 2021 ofCHF25.2M ($26.7M) -- Completed $11.5Mfundraising in January 2021 -- Three clinical studies in neurology programsremain on track to start during Q22021 -- Neurology programs aimed at large underserved market opportunitiesindyskinesia associated with Parkinsons disease, blepharospasm and epilepsy GlobeNewswire Inc

May 3, 2021

01:00AM EDT Addex Therapeutics to Release Q1 2021 Financial Results and Host GlobeNewswire Inc

Apr 26, 2021

01:00AM EDT Geneva, Switzerland, April26, 2021- Addex TherapeuticsLtd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will present at the 4 Annual Neuroscience Innovation Forum (April 26 - 30, 2021). GlobeNewswire Inc

01:00AM EDT Addex Increases Issued Share Capital to Create Treasury Shares GlobeNewswire Inc

Apr 21, 2021

01:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 Benzinga

06:29AM EDT HC Wainwright & Co. Initiates Coverage On Addex Therapeutics with Buy Rating, Announces Price Target of $28 Benzinga

Apr 13, 2021

01:00AM EDT Geneva, Switzerland, April 13, 2021- Addex TherapeuticsLtd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will present at the 20th Annual Needham Virtual Healthcare Conference (April 12-15, 2021). GlobeNewswire Inc

Apr 8, 2021

01:00AM EDT Addex Files Registration Statement on Form F-3 with the US GlobeNewswire Inc

Apr 7, 2021

04:10PM EDT Addex Therapeutics Files For Stock Shelf Of Up To $150M Benzinga

Mar 11, 2021

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

01:00AM EST -- Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) -- Balance sheet further strengthened by $11.5M fundraising on January 11, 2021 -- Three clinical studies in neurology programs expected to start during H1 2021 -- Clinical stage neurology programs aimed at large underserved market opportunities (Epilepsy, Parkinsons disease LID and Blepharospasm) GlobeNewswire Inc

Mar 9, 2021

01:00AM EST Addex Therapeutics to Release Full-Year 2020 Financial Results and GlobeNewswire Inc

Mar 8, 2021

04:05AM EST Earnings Scheduled For March 8, 2021 Benzinga

Mar 4, 2021

01:00AM EST Geneva, Switzerland, March 4, 2021- Addex TherapeuticsLtd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,will present at the H.C. Wainwright Global Life Sciences Conference (March 9-10, 2021). GlobeNewswire Inc

Feb 24, 2021

04:15AM EST Enamine Extend Collaboration With Addex Therapeutics RTTNews

04:00AM EST Enamine Extend Collaboration With Prominent Swiss Biotech Business Wire

Feb 17, 2021

01:00AM EST Geneva, Switzerland, February 17, 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents. GlobeNewswire Inc

Feb 16, 2021

12:52PM EST Addex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use Disorder Benzinga

01:00AM EST Review from Linkping University Published in Alcohol and Alcoholism Journal GlobeNewswire Inc

Jan 22, 2021

06:13AM EST Addex Therapeutics 13D Filing From Growth Equity Opportunities Fund Shows 21.5% Stake Benzinga

Jan 21, 2021

10:05AM EST Shares of Addex Therapeutics Ltd (ADXN) are rising more than 40% Thursday morning after its partner Janssen Pharmaceuticals, a unit of Johnson & Johnson, received Investigational New Drug (IND) approval from the FDA to start a Phase 2a study of JNJ-40411813 (ADX71149) in patients with epilepsy. RTTNews

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

05:28AM EST Addex Therapeutics Announced its ADX71149 Received FDA IND Approval to Start a Phase 2a Clinical Study in Epilepsy; Shares Trading Up 120% in Premarket Benzinga

01:04AM EST Addex Therapeutics Receives IND Approval For ADX71149 From FDA To Start Phase 2a Clinical Study In Epilepsy RTTNews

01:00AM EST First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 GlobeNewswire Inc

Jan 12, 2021

01:00AM EST Geneva, Switzerland, January 12, 2021- Addex TherapeuticsLtd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer,is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 January 15, 2021. GlobeNewswire Inc

Jan 11, 2021

04:00PM EST Addex Successfully Completes $11.5 Million Capital Increase GlobeNewswire Inc

Jan 7, 2021

03:14PM EST Mid-Afternoon Market Update: Dow Rises 250 Points; 3D Systems Shares Spike Higher Benzinga

01:16PM EST Mid-Day Market Update: Nasdaq Jumps 280 Points; Addex Therapeutics Shares Plummet Benzinga

10:55AM EST Mid-Morning Market Update: Markets Open Higher; Walgreens Beats Q1 Expectations Benzinga

Jan 6, 2021

10:39PM EST Addex Therapeutics Prices Underwritten Global Offering Of 6 Mln Shares At $10.00/ADS RTTNews

09:00PM EST Addex Announces Pricing of $10.0 Million Global Offering GlobeNewswire Inc

Dec 28, 2020

02:31PM EST Mid-Afternoon Market Update: Nasdaq Jumps Over 100 Points; AeroCentury Shares Spike Higher Benzinga

01:57PM EST Mid-Day Market Update: Dow Surges 240 Points; Aprea Therapeutics Shares Plunge Benzinga

10:21AM EST Mid-Morning Market Update: Markets Open Higher; President Trump Signs $900B Covid-19 Relief Bill Benzinga

Dec 14, 2020

12:22PM EST Addex Announces Filing of Registration Statement for Proposed GlobeNewswire Inc

Nov 3, 2020

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

01:00AM EST Geneva, Switzerland, November 3, 2020 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its third quarter financial results and provided an update on corporate activities. GlobeNewswire Inc

Nov 2, 2020

01:06AM EST ADDEX THERAPEUTICS TO RELEASE Q3 2020 FINANCIAL RESULTS AND HOST GlobeNewswire Inc

01:00AM EST Addex Receives Additional $2.8 million from Indivior and Extends GlobeNewswire Inc

Sep 23, 2020

01:00AM EDT Geneva, Switzerland, September 23, 2020- Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that Tim Dyer, Chief Executive Officer,is scheduled to participate at the Investora Conference taking place in Zurich, Switzerland on September 23 September 24, 2020. GlobeNewswire Inc

Sep 14, 2020

01:00AM EDT Geneva, Switzerland, September 14, 2020- Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that Tim Dyer, Chief Executive Officer,is scheduled to participate at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference taking place on September 14 September 16, 2020. GlobeNewswire Inc

Aug 31, 2020

01:00AM EDT Geneva, Switzerland, August 31, 2020- Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that that Tim Dyer, Chief Executive Officer,is scheduled to participate at the Biotechgate Digital Partnering Conference taking place on August 31 September 3, 2020. GlobeNewswire Inc

Aug 27, 2020

01:00AM EDT ADX10061 Previously Demonstrated Favorable Safety and Tolerability in Clinical Studies GlobeNewswire Inc

Aug 12, 2020

01:00AM EDT Geneva, Switzerland, August 12, 2020 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its second quarter and half year financial results for the periods ended June 30, 2020 and provided an update on corporate activities. GlobeNewswire Inc

Aug 10, 2020

01:00AM EDT Addex Therapeutics to Release Half-Year 2020 Financial Results and GlobeNewswire Inc

Aug 6, 2020

01:00AM EDT Geneva, Switzerland, August 6, 2020- Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer,will participate in the BTIG Virtual Biotechnology Conference taking place on August 10 11, 2020. GlobeNewswire Inc

Jul 20, 2020

01:00AM EDT Van Leeuwenhoeck Issues Updated Addex Equity Research Report GlobeNewswire Inc

Share